Director at Climb Bio (CLYM) sells 50,000 shares in planned trades

Rhea-AI Filing Summary

Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 50,000 shares of Common Stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On February 25, 2026, he sold 33,687 shares at a weighted average price of $7.0046 per share, followed by 16,313 shares on February 26, 2026 at a weighted average price of $7.0060 per share. The filing notes that each day’s sales occurred in multiple trades within price ranges from $7.0000 to $7.0600 and from $7.0000 to $7.0400, respectively. After these transactions, Basil directly owned 154,657 shares.

Insider Trade Summary

Net Seller: 50,000 shares ($350,253)

Net Sell 2 txns

Insider Thomas Stephen Basil

Role Director

Sold 50,000 shs ($350K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,313	$7.006	$114K
Sale	Common Stock	33,687	$7.0046	$236K

Holdings After Transaction: Common Stock — 154,657 shares (Direct)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas Stephen Basil

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		33,687	D	$7.0046(2)	170,970	D
Common Stock	02/26/2026		S(1)		16,313	D	$7.006(3)	154,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.

	/s/ Chandra Adams, as Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Climb Bio (CLYM) director Thomas Basil report on this Form 4?

He reported selling a total of 50,000 Climb Bio common shares in two open-market transactions. The sales were executed under a Rule 10b5-1 trading plan and left him with 154,657 directly owned shares afterward.

Over what dates did Thomas Basil sell Climb Bio (CLYM) shares and how many?

He sold 33,687 Climb Bio common shares on February 25, 2026 and 16,313 shares on February 26, 2026. Together, these transactions totaled 50,000 shares sold in the open market.

What prices did Climb Bio (CLYM) director Thomas Basil receive for the sold shares?

The February 25, 2026 sale had a weighted average price of $7.0046 per share, with trades between $7.0000 and $7.0600. The February 26, 2026 sale averaged $7.0060 per share, with trades between $7.0000 and $7.0400.

How many Climb Bio (CLYM) shares does Thomas Basil own after these transactions?

After completing the reported sales, Thomas Basil directly owned 154,657 shares of Climb Bio common stock. This figure reflects his holdings immediately following the February 26, 2026 open-market transaction.

Was the Climb Bio (CLYM) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Thomas Basil on October 14, 2025. Such plans pre-arrange trade timing and size, helping separate sales from day-to-day discretion.